Pieris Pharmaceuticals Stock Performance
| PIRS Stock | USD 16.84 0.07 0.42% |
The company holds a Beta of 0.59, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pieris Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pieris Pharmaceuticals is expected to be smaller as well. At this point, Pieris Pharmaceuticals has a negative expected return of -0.004%. Please make sure to check Pieris Pharmaceuticals' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Pieris Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pieris Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Pieris Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 2.29 | Five Day Return 8.92 | Year To Date Return 13.96 | Ten Year Return (92.28) | All Time Return (92.28) |
Last Split Factor 1:80 | Last Split Date 2024-04-23 |
1 | PIRS Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders | 09/03/2024 |
2 | Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance Annual Conference | 10/15/2024 |
3 | Acquisition by Geraghty James A of tradable shares of Pieris Pharmaceuticals at 1.0 subject to Rule 16b-3 | 10/28/2024 |
4 | Insider Trading | 11/06/2024 |
5 | Pieris Pharmaceuticals Q3 Earnings Snapshot | 11/13/2024 |
6 | PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIR... | 11/20/2024 |
| Begin Period Cash Flow | 38.6 M |
Pieris |
Pieris Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,714 in Pieris Pharmaceuticals on August 28, 2024 and sell it today you would lose (30.00) from holding Pieris Pharmaceuticals or give up 1.75% of portfolio value over 90 days. Pieris Pharmaceuticals is currently does not generate positive expected returns and assumes 2.2182% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Pieris, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pieris Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pieris Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pieris Pharmaceuticals, and traders can use it to determine the average amount a Pieris Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0018
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PIRS |
Estimated Market Risk
| 2.22 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pieris Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pieris Pharmaceuticals by adding Pieris Pharmaceuticals to a well-diversified portfolio.
Pieris Pharmaceuticals Fundamentals Growth
Pieris Stock prices reflect investors' perceptions of the future prospects and financial health of Pieris Pharmaceuticals, and Pieris Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pieris Stock performance.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | (4.22 M) | ||||
| Shares Outstanding | 1.32 M | ||||
| Price To Earning | (6.95) X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 1.06 X | ||||
| Revenue | 42.81 M | ||||
| Gross Profit | (27.08 M) | ||||
| EBITDA | (22.76 M) | ||||
| Net Income | (24.54 M) | ||||
| Cash And Equivalents | 80.94 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 11.92 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 2.56 X | ||||
| Book Value Per Share | 21.64 X | ||||
| Cash Flow From Operations | (53.82 M) | ||||
| Earnings Per Share | (12.11) X | ||||
| Market Capitalization | 21.14 M | ||||
| Total Asset | 38.68 M | ||||
| Retained Earnings | (314.96 M) | ||||
| Working Capital | 36.84 M | ||||
| Current Asset | 31.66 M | ||||
| Current Liabilities | 2.8 M | ||||
About Pieris Pharmaceuticals Performance
Assessing Pieris Pharmaceuticals' fundamental ratios provides investors with valuable insights into Pieris Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pieris Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.67) | |
| Return On Capital Employed | (1.11) | (1.17) | |
| Return On Assets | (0.63) | (0.67) | |
| Return On Equity | (0.92) | (0.96) |
Things to note about Pieris Pharmaceuticals performance evaluation
Checking the ongoing alerts about Pieris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pieris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pieris Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pieris Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M). | |
| Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09. | |
| Pieris Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Marketscreener.com |
- Analyzing Pieris Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pieris Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Pieris Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pieris Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pieris Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pieris Pharmaceuticals' stock. These opinions can provide insight into Pieris Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.